A Comparative Study of Lipid Profile in Pre-Dialysis and Post-Dialysis End-Stage Renal Disease Patients

Year : 2026 | Volume : 16 | Issue : 01 | Page : 25 31
    By

    Kaushal Kumar Goyal,

  • Ravi Prakash Nagar,

  • Ankita Mittal,

  • Gulab Kanwar,

  • Mukesh Vijayvergiya,

  1. Postgraduate Resident, Department of Biochemistry, Government Medical College, Kota, Rajasthan, India
  2. Postgraduate Resident, Department of Biochemistry, Government Medical College, Kota, Rajasthan, India
  3. Postgraduate Resident, Department of Biochemistry, Government Medical College, Kota, Rajasthan, India
  4. Senior Professor and Head, Department of Biochemistry, Government Medical College, Kota, Rajasthan, India
  5. Professor, Department of Biochemistry, Government Medical College, Kota, Rajasthan, India

Abstract

Background: Chronic kidney disease (CKD) represents a major public health concern in India, with its prevalence increasing at an alarming rate. Individuals with CKD are at a substantially higher risk of developing cardiovascular disease (CVD), which remains the leading cause of mortality in this population. Dyslipidemia is particularly pronounced among patients with end-stage renal disease (ESRD); however, limited data are available regarding the impact of hemodialysis on lipid profile alterations. Therefore, the present study was undertaken to evaluate the effect of hemodialysis on lipid parameters in patients with CKD. Materials and Methods: A cross-sectional study involving 131 CKD patients receiving hemodialysis Between November 2023 and October 2024, at Government Medical College and Associated Hospitals Kota in Rajasthan, India, was carried out. Using an autoanalyzer, the serum lipid profile was examined both before and after the hemodialysis session. Before and after hemodialysis, the mean values of various lipid parameters were calculated and the difference between the two was compared using a paired t-test. Statistical significance was defined as a p-value < 0.05. Results: Low-density lipoprotein (LDL) levels considerably dropped after hemodialysis in this study. The levels of Triglycerides (TG), Very low-density lipoprotein (VLDL), and Total cholesterol (TC) were all significantly decreased. The only lipoprotein to rise following dialysis was High-density lipoprotein (HDL). Conclusion: CKD patients can benefit from adequate dialysis and time-bound monitoring of specific lipid profile components by lowering their risks for cardiovascular problems.

Keywords: Chronic kidney disease, dyslipidemia, end-stage renal disease, hemodialysis, lipid profile

[This article belongs to Research and Reviews: A Journal of Medicine ]

How to cite this article:
Kaushal Kumar Goyal, Ravi Prakash Nagar, Ankita Mittal, Gulab Kanwar, Mukesh Vijayvergiya. A Comparative Study of Lipid Profile in Pre-Dialysis and Post-Dialysis End-Stage Renal Disease Patients. Research and Reviews: A Journal of Medicine. 2026; 16(01):25-31.
How to cite this URL:
Kaushal Kumar Goyal, Ravi Prakash Nagar, Ankita Mittal, Gulab Kanwar, Mukesh Vijayvergiya. A Comparative Study of Lipid Profile in Pre-Dialysis and Post-Dialysis End-Stage Renal Disease Patients. Research and Reviews: A Journal of Medicine. 2026; 16(01):25-31. Available from: https://journals.stmjournals.com/rrjom/article=2026/view=240096


References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Chapter 1: Definition and classification of chronic kidney disease. Kidney Int Suppl. 2013;3(1):19–62.
  2. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and chronic kidney disease: 2012 update. Am J Kidney Dis. 2012;60(5):850–886. doi: 10.1053/j.ajkd.2012.07.005. Erratum in: Am J Kidney Dis. 2013 Jun;61(6):1049. PMID: 23067652.
  3. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: A neglected subgroup. Heart Asia. 2016;8(1):56–61.
  4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–352.
  5. Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: Etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.
  6. Akpan EE, Ekrikpo UE, Effa EE, Udo AI, Kadiri S. Assessment of dyslipidemia in pre-dialysis patients in south-west Nigeria. Niger Med J. 2014;55(3):214–219.
  7. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities study. J Am Soc Nephrol. 2005;16(2):529–538.
  8. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–147.
  9. Kim KM, Oh HJ, Choi HY, Lee H, Ryu DR. Impact of chronic kidney disease on mortality: A nationwide cohort study. Kidney Res Clin Pract. 2019;38(3):382–390.
  10. Latha KM, Varma BA. Pre- and post-dialysis variations in serum lipid profile among end-stage renal disease patients. J Clin Diagn Res. 2018;12(5):BC05–BC09.
  11. Chijioke NN, Bartimaeus EA, Okeke CU. Lipid profile in chronic renal failure patients on dialysis. Eur J Cardiovasc Med. 2012;2(2):106–109.
  12. Nagane NS, Ganu JV. Lipid profile and serum paraoxonase-1 activity in chronic renal failure patients before and after haemodialysis. Al Ameen J Med Sci. 2011;4(1):61–68.
  13. Baldi S, Innocenti M, Frascerra S, Nannipieri M, Lippi A, Rindi P, et al. Effects of hemodialysis and vitamin E supplementation on low-density lipoprotein oxidizability in end-stage renal failure. J Nephrol. 2013;26(3):549–555.
  14. Tsitamidou R, Kynigopoulou K, Dimitriadis G, Tsardaki M, Sombolos K. Natural anticoagulants and lipid profile in hemodialysis patients. Hippokratia. 2009;13(2):28–31.
  15. Zulbeari L, Cakalaroski K, Gruev T, Arsova V, Zulbeari E. Lipid profile and concentration of apolipoprotein A-1 and apolipoprotein B-100 in patients with end-stage renal disease treated with repeated haemodialysis. Prilozi. 2008;29(1):141–152.
  16. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol. 1993;3(8):1409–1415.
Regular Issue Subscription Original Research
Volume 16
Issue 01
Received 29/12/2025
Accepted 28/01/2026
Published 28/02/2026
Publication Time 61 Days
7

Login


My IP

PlumX Metrics